In order to achieve the maximum therapeutic benefit in the treatment of malignancies, doses of chemotherapeutic agents are pushed to the point of severe marrow toxicity. This aggressive therapy can lead to iatrogenic complications including haemorrhage and sepsis due to the depletion of platelets and granulocytes. Prior to the advent of platelet transfusions, haemorrhage was the leading cause of death in these patients. 1 Advances in blood banking and the availability of platelet transfusions have markedly " decreased the incidence of fatal haemorrhage. As a result, infection has become the leading cause of death in patients with marrow failure. 2 Although the risk of infection in patients with neutropenia has been well documented,3 the role of granulocyte transfusions in the treatment and prevention of these infections remains controversial. This paper will attempt to review the currently available literature regarding granulocyte procurement techniques and the efficacy of granulocyte transfusions.
that one must make available to the recipient. Due to these restraints, a method that processes a large volume of blood and concentrates granulocytes from the donor is necessary. One additional option is the use of granulocytes from donors with chronic myelogenous leukaemia (CML). In such patients, the high peripheral white counts obviate the need for concentration techniques. This method was used prior to the availability of current techniques for granulocyte procurement. 6 However, the availability of patients with chronic myelogenous leukaemia is limited. Furthermore, in these early studies that used patients with CML as donors, some of the recipients engrafted with CML cells. 6 Currently available techniques for granulocyte collection involve the circulation of donor blood through a specialised apparatus which removes granulocytes and returns the blood to the donor. Granulocyte removal is accomplished using either a centrifuge apparatus or a nylon fibre filter. Anticoagulation is required since donor blood contacts a foreign surface.
The first technique used for granulocyte procurement from the normal donor was described by Djerassi et aJ. 1 The technique, known as filtration leukapheresis, involves passing donor blood over a nylon fibre filter. During the extracorporeal flow, granulocytes adhere to the nylon fibres. The process takes two to three hours with an extracorporeal volume of 200 to 300 m!. When completed, the nylon fibre circuit is flushed with a solution of ACD-saline-heparin to remove the granulocytes. The granulocyte suspension is concentrated and infused into the recipient.
In centrifugal cell separators, the donor blood passes into a centrifuge bowl. The blood is centrifuged and separated into three layers: erythrocytes, granulocytes, and plasma. The granulocytes are removed while the blood and plasma are returned to the donor. Variations on this method involve either continuous-or intermittent-flow devices. In the continuous-flow devices, blood is continuously added to and removed from the bowl so that the only change in blood volume after the initial filling of the bowl is the slow loss of granulocytes and buffy coat (normally 300 to 600 ml for the entire procedure). With the intermittent variety, the filling of the centrifuge device and emptying are two separate processes. After granulocyte collection, the remaining erythrocytes and plasma are reinfused into the recipient while the bowl is refilled. During this process, 500 ml of donor blood are extracorporeal and the volume changes are intermittent. The intermittent device requires the use of ACD (acid-citrate-dextrose) anticoagulant which may be associated with a higher incidence of side-effects than the heparin anticoagulation used with the continuous centrifuge method.
The goal of collection for adults is to obtain 2 X 10 10 granulocytes per transfusion. 8 As mentioned previously, this requires the processing of a large volume of blood. The granulocyte yield depends on both the volume of blood processed and the peripheral granulocyte count of the donor. Several techniques have been introduced to increase the granulocyte yield. To improve separation of granulocytes from erythrocytes in centrifugal collectors, a sedimenting agent can be added to the blood. This agent increases the density of the erythrocytes. The most commonly used agent is hydroxyethyl starch which increases the granulocyte yield by a factor of 3 to 5. 9 Another method of increasing the yield is by increasing the peripheral granulocyte count ofthe donor. This can be accomplished with an oral dose of corticosteroid four to six hours prior to the procedure. 10,1 I Aside from the quantity of granulocytes obtained, concern has been expressed over the quality (function) of donor granulocytes. Although the numbers obtained by filtration methods are greater, controversy exists concerning their function. There is some evidence that filtration Despite these apparent shortcomings, unlike centrifugation techniques, filtration leukapheresis is inexpensive and easy to establish at any institution. Furthermore, filtration leukapheresis results in a higher yield of granulocytes per unit time than continuous or intermittent flow centrifugation. More recently, the studies concerning the efficacy of filtration obtained granulocytes have been questioned. Although the granulocytes have abnormal findings on electron microscopy and abnormal in vitro activity, a prospective study by Higby et at. demonstrated that granulocytes obtained by filtration leukapheresis significantly improved survival in granulocytopenic patients (WBC count less than 500/mm 3 ) with documented infections. 13 In addition to the previously mentioned problems encountered with obtaining granulocytes, one must also consider the risks to the donor. Granulocyte procurement techniques require the availability of the donor for two to four hours per day for the duration of the therapy. In most studies (which will be discussed later), transfusions are continued anywhere from four to six days or until the patient's own marrow returns. Although the same donor does not have to be used every day, this is frequently the case since a relative or close family member is generally used, due to the time constraints of the donation process.
Since granulocyte procurement requires the extracorporeal circulation of blood (300 to 500 ml) and 16 gauge cannulae for blood withdrawal and return, donor age is restricted to greater than eighteen years and weight to greater than 50 kilograms. Even following these guidelines, some donors may be unsuitable due to inadequate venous access.
Hypotension and lightheadedness can occur and relate to changes in blood volume during the pheresis process. These minor adverse effects are more common in machines that require a large extracorporeal volume of blood. Donor complications related to heparin anticoagulation or the administration of hydroxyethyl starch or steroids have not been reported. However, donors with contraindications to anticoagulation are excluded. ACD anticoagulation has been associated with paraesthesias and nausea related to changes to ionized calcium concentrations. 16 Clift et al. reported significant complications in donors in their randomised study. 17 Donors in this study had arterio-venous shunts placed to facilitate leukapheresis. Of the 36 donors with shunts, four had recurrent problems with clotting which required termination of donation in two cases. One patient became disconnected during leukapheresis and lost a significant amount of blood resulting in shock that required emergency therapy. In one other patient, leukapheresis was stopped due to severe abdominal pain of unknown aetiology which resolved after the termination of the procedure.
Although leukapheresis is generally safe for the donor, careful selection of patients without preexisting medical problems will help limit the possibility of mishaps. Additional concerns include the drop in haematocrit seen after centrifugation techniques (0.5 to 0.9% per day). Therefore, the donor should receive daily iron therapy ifhe is used repeatedly for leukapheresis.
Granulocyte transfusions -clinical and laboratory studies
The era of granulocyte transfusions began in 1964. Freireich et al. administered granulocyte transfusions obtained from patients with chronic myelogenous leukaemia to granulocytopenic patients who had failed to respond to antibiotic therapy.6 Although previous attempts had been made with granulocyte transfusions, normal donors had been used. Therefore, with the technique available at the time, sufficient numbers of granulocytes could not be collected.
In their non-randomized study, Freierich et al. evaluated the efficacy of granulocyte transfusions in febrile, neutropenic patients. Eighty of the patients who received transfusions were febrile at the time. Of these eighty, fever resolved in 54%. Twenty-four of the febrile patients had positive blood cultures despite antibiotic therapy (colymycinlstaphcillin). Of the twenty-one with blood cultures positive for a gram negative rod, fourteen (67%) became afebrile and nine (43%) were cured (remained well for at least two weeks). Most impressive were the results in patients with blood cultures positive for Pseudomonas in the era prior to effective antimicrobial therapy for this organism. Seven of thirteen (54%) patients had resolution of their infection and negative blood cultures.
In addition to the evaluation of clinical responses and efficacy, Freireich et al. were the first to study the effects of granulocyte doses and the eventual fate of the transfused cells. They found that the post-transfusion increase in granulocyte count was directly related to the dose of granulocytes. The efficacy in reducing fever was also found to be linearly related to the dose of granulocytes. With the Rebuck skin window, they demonstrated that transfused granulocytes were functional.
This initial success with granulocyte transfusions encouraged the pursuit of further clinical and laboratory investigations in this field. 18 ,19 Initial work focused on the problems of harvesting granulocytes. In 1969, Epstein et al. published their work in dogs with the use of continuous-flow centrifugation. IS In this study, granulocytes were transfused to animals with E. coli sepsis and neutropenia induced by total blood irradiation. Granulocyte transfusions effectively sterilised subsequent blood cultures and prolonged survival when compared to the control group. Furthermore, this study demonstrated that irradiated granulocytes were as effective as non-irradiated granulocytes.
The availability of continuous-flow centrifugation and other advances in granulocyte procurement provided the knowledge and techniques necessary for subsequent clinical trials. When evaluating the available clinical studies, it will become apparent that several variables exist. Many of these studies are non-randomised and use various criteria to define success. Some studies use objective criteria such as resolution of bacteraemia or survival time while others use softer criteria such as fever resolution or a subjective sense of wellbeing. Additionally, the patient populations vary. Some include all patients with neutropenia while others are limited to bone marrow transplant patients or patients with a specific malignancy. Furthermore, the lower limit of acceptable granulocyte counts vary from study to study (250 to 1000/mm 3 ) . Other problems arise in that different criteria are used as to when to give granulocyte transfusions. In one study they are given prophylactically, while in other studies they are given empirically in patients with fever, in documented infections, in suspected infections, or in infections that have failed to respond to appropriate antibiotic therapy. Furthermore, the duration of therapy varies with granulocytes being administered once, daily for four to seven days, until neutropenia resolves, or until the infection or septicaemia has resolved. Therefore when considering the various studies evaluating the efficacy of granulocyte transfusions, several variables exist and must be taken into account.
Since the use of granulocyte transfusions without the simultaneous use of antibiotics is unthinkable, the question to be answered is: do granulocyte transfusions add anything to the use of appropriate antibiotic therapy in neutropenic patients? In our review we found sixteen studies (randomized and non-randomized) in adult patients evaluating the efficacy of granulocyte transfusions. Unlike the study of Freireich et al. when effective antipseudonomal therapy was not available, these studies were done during the modem era of antibiotic therapy. Of these sixteen studies, ten evaluated the use of granulocyte transfusions to treat suspected or documented infections I 1,13,14,20-26 while SiX 17 ,27-31 evaluated the efficacy of Of the ten studies in adults, five are randomized and five are non-randomized (Tables 1 and 2) . Eight of the studies (four randomized and four nonrandomized) conclude that granulocyte transfusions decreased the duration of fever, hastened the resolution of infection, or improved patient outcome. The most impressive results are reported by the studies of Higby et al. 13 and Herzig et al. 22 In the randomized study of Higby et al., five· of nineteen patients in the control group survived to day 20 while fifteen of seventeen in the transfusion group survived (P < 0.05).
Summary of clinical trials in adults
Granulocyte transfusions were administered to patients with counts less than 500/mm3, clinical evidence of infection, and failure to respond to 48 hours of appropriate antibiotics. Granulocyte transfusions were administered daily for four days.
In the randomized study of Herzig et aI., five of fourteen control patients survived while twelve of sixteen in the transfusion group survived (P < 0.04). More impressive was the result in the patients who had prolonged marrow failure (granulocyte less than 1000/mm3 for more than ten days) with a positive blood culture. In this subpopulation of patients, only two of nine control patients survived while nine of twelve in the transfusion group survived (P < 0.025). This study included patients with documented gram-negative bacteraemia. Granulocyte transfusions were administered daily until granulocyte counts returned (greater than 1000/mm3).
Further evidence for the value of granulocyte transfusions in patients with persistent neutropenia is presented in the study of Alavi et al. 2l They reported a 20% survival in the control population and a 75% survival in the transfusion group for patients with prolonged marrow failure. Granulocytes were administered daily to patients with counts less than 250/mm 3 and continued until the marrow recovered. They found no difference in survival in patients with fever unrelated to infection and concluded that. granulocyte transfusions should be discontinued if cultures are negative.
The issue is clouded by the most recent randomized study of Winston et a/. 25 They demonstrated no improvement in survival with granulocyte transfusions. A response was noted in 34 of 47 control patients and 30 of 48 treated patients. Patients received daily granulocyte transfusions until counts were greater than 500/mm 3 . No difference in response was noted when the various subpopulations were examined including patients with gram-positive sepsis, gram-negative sepsis, or gram-negative sepsis with persistent marrow failure. Concerns were expressed about previous randomized studies suggesting that patient numbers were smaller (less than twenty patients in the control or treatment groups) while this current study included 95 patients. Of particular interest in this study is the high survival rate (72%) in the control group. This contrasts with other studies in which the control group survival varies from 20 to 40%. One explanation offered is the difference in antibiotic therapy between this current study (1982) and the previous studies (1972) (1973) (1974) (1975) (1976) (1977) . Furthermore the treatment regimens used in acute leukaemia have improved, resulting in shorter periods of neutropenia with quicker remission induction. This study brings up one of the major problems in effectively evaluating and comparing these clinical trials. The rapid improvements in cancer treatment and supportive care from the 1970s to the current time have made it even more difficult to evaluate the efficacy of granulocyte transfusions.
The next question raised concerning granulocyte transfusions was their prophylatic use. We were able to find six randomized studies attempting to answer this questionY·27.3l Except for the most recent of these studies,29 prophylactic granulocyte transfusions decreased the incidence of infection. However, the results were statistically significant in only two of the studies. 17 . 28 Furthermore, despite the possible decreased incidence of infection, no difference in survival was noted in any of the studies. One possible explanation is that any benefit must be weighed against the morbidity and mortality incurred by granulocyte transfusions including pulmonary toxicity and interstitial pneumonitis from cytomegalovirus (these risks will be discussed later).
One major criticism that has been raised concerning the various trials of granulocyte transfusions in adults has been both the variations in daily doses of granulocyte and concerns about the inadequacy of these doses. In the various studies that we have reviewed, a wide range of daily doses exist, ranging from 5 X 10 9 to 5.9 X 1010. Even with the highest doses, this still represents a fraction of the total daily turnover of granulocytes. With currently available techniques, the use of higher doses of granulocytes is impossible.
In the paediatric and neonatal population, larger doses are possible due to the size of the recipient. Despite this, we found no randomized study evaluating the efficacy of granulocyte transfusions in the paediatric population. Although some of the randomized, controlled studies have included children, their numbers are limited. Despite the dramatic results and responses in non-randomized paediatric studies,32-35 controlled, randomized Prevention requires the use of cytomegalovirusstudies are necessary_ negative blood products in seronegative recipients. Experience with granulocyte transfusions is also Although this will decrease the risk of CMV limited in the neonatal population. Efficacy has infection, it will also further limit the already small been suggested by two studies (one randomized and donor pool. one non-randomized) using granulocytes obtained
In addition to granulocytes, leukocyte by either intermittent-or continuous-flow transfusions also contain immunocompetent centrifugation. 36 ,37 The randomized, prospective lymphocytes. The literature contains well study of Christensen et al. 36 evaluated granulocyte documented cases of acute graft-versus-host transfusions in 26 neonates with bacterial disease (several of which were fatal) resulting from infections and neutropenia (less than 1500/m 3 ). the use of granulocyte transfusions,43,44 The cases Granulocytes were obtained by continuous-flow were acute in onset (six to ten days) with the typical centrifugation and administered in a dose of 15 manifestations of acute graft-versus-host including mllkg every twelve hours for a total of five doses. rash, diarrhoea, liver dysfunction and This resulted in granulocyte doses of 0.2 to pancytopenia. As with other blood products, the 1.0 X 10 9 /kg. Seven of seven neonates in the irradiation of leukocyte transfusions can eliminate treatment group survived while only one of nine in this complication. Despite this, the irradiation of the control group survived (P < 0.01).
leukocyte transfusions is not a universally accepted
In contrast, two studies evaluating buffy coat procedure and in fact many of the trials from the transfusions have failed to show a clinical literature did not routinely irradiate the response. 38 ,39 The major difference between these granulocyte transfusions. studies is the technique of granulocyte Perhaps the most important complications procurement with significantly lower doses of related to granulocyte transfusions are their effects granulocytes with buffy coat preparations. on the pulmonary system. In addition to the risk of Complications of granulocyte transfusions interstitial pneumonitis due to cytomegalovirus Interest in evaluating the efficacy of granulocyte infections, several other pulmonary toxicities of transfusions persists since their use is not granulocyte transfusions have been described. [45] [46] [47] [48] innocuous and incurs risk to both the donor and the Acute reactions include bronchospasm, wheezing, recipient. Donor complications have been and cough. Postulated mechanisms include fluid described previously in this paper and we will now overload in patients with compromised left focus on the hazards to the recipient. ventricular function, complement activation, or Acute reactions occurring during the infusion of the aggregation and embolization of granulocytes granulocytes are presumed to result from the in the pulmonary vasculature due to the presence of activation of granulocyte granules and the release ,leukoagglutinins in the recipient. 4 5-47 of cytokines. Although premedication with New infiltrates on chest radiograph have been antipyretics and antihistamines is recommended identified in up to 25% of patients receiving for all recipients, fever and hypotension still occur granulocyte transfusions 25 ,48 and in controlled in 10 to 15% of recipients. Other acute studies, patients given granulocyte transfusions manifestations include shivering, urticaria, and have a higher incidence of infiltrates on chest one reported case of laryngospasm. 21 Milder X-ray.29 These infiltrates are often transient and reactions can be treated by slowing the infusion rate unaccompanied by evidence of clinical and the administration of antihistamines, deterioration. Additionally, severe pulmonary antipyretics and corticosteroids, while more severe toxicity has been reported associated with the reactions require the termination of the concomitant administration of granulocytes and transfusions. These cytokine-mediated reactions amphotericin B.49,50 Controversy exists over the may be more common in cells obtained by exact incidence and mechanism of this reaction. filtration leukapheresis, as the adherence of Karp et at. showed no difference in the incidence of granulocytes to the nylon fibres may cause granule pulmonary toxicity in patients on and off activation.4o amphotericin B.48 Therefore we do not currently As with most blood products, the possibility limit the use of amphotericin B in patients also exists for the transmission of blood-borne diseases receiving granulocyte transfusions. However, given including toxoplasmosis, hepatitis, malaria, the the controversy surrounding this issue, we acquired immunodeficiency virus, and recommend separating the two infusions cytomegalovirus. Cytomegalovirus transmission is (amphotericin Band granulocytes) by six to eight particularly worrisome as it is a leading cause of hours. interstitial pneumonitis and mortality in patients Aside from the risk of pulmonary toxicity in undergoing bone marrow transplantation. 41 ,42 recipients with le~koagglutinins, it has been suggested that granulocyte function is impaired in patients with leukoagglutinins. 46 . 51 However, no correlation between HLA matching and survival can be shown and therefore HLA matching of donor and recipient is not thought to be necessary for the successful use of granulocyte transfusions. 24 This is presumed to be a result of the low density of HLA antigens on mature granulocytes. 52 One exception is patients for bone marrow transplantation. In these patients, it is postulated that HLA-matched granulocytes may prevent sensitization to HLA antigens and improve the chances of engraftment.
Finally when considering granulocyte transfusions, it is impossible to ignore the time and cost involved. In addition to time requirements of the blood banking staff and equipment, the procedure is time-consuming for the donor. These procedures require two to four hours per day and in some instances the same donor is used for four to five days. Cost estimates vary from centre to centre, but range from $30,000 to $50,000 for a four to seven day course of treatment. 53 CONCLUSION Any conclusions regarding the efficacy of granulocyte transfusions must be evaluated considering the currently available antibiotic and supportive therapies. Although the use of granulocyte transfusions may have been very beneficial in 1963 in patients with Pseudomonas sepsis, their use in this day and age may be antiquated by effective anti-pseudomonal therapy. It is therefore difficult to evaluate even recent trials (1970s) since ancillary therapies change rapidly. Furthermore, data are even more limited concerning the efficacy of granulocyte transfusions in non-bacterial infections (i.e. fungal) and in patients with qualitative defects of leukocyte function, although case reports have suggested their efficacy in patients with chronic granulomatous disease. 34. 54 In addition to advances in antimicrobial agents and supportive care, other therapeutic advances may limit the need for granulocyte transfusions. The most recent of these advances is the availability of colony-stimulating factors produced through recombinant DNA technology. The growth factors are a heterogenous group of glycoproteins that control the differentiation and maturation of the normal blood elements. Although the number of growth factors controlling haematopoietic cell growth and lineage commitment is extensive, only six are currently available for clinical use. These include GM-CSF (granulocyte-macrophage colony stimulating factor), G-CSF (granulocyte colony stimulating factor), M-CSF (macrophage colony stimulating factor), and the interleukins (IL-I, IL-II, and IL-III).
Following the successful production of significant quantities of the colony stimulating factors, several clinical studies have been undertaken to evaluate the toxicity and efficacy of these agents. Trials have included patients with marrow failure of several aetiologies including aplastic anaemia,55 idiopathic neutropenia,56 congenital agranulocytosis 57 and chemotherapyinduced neutropenia. 58 . 6o Early reports suggest that these agents may effectively limit the period of neutropenia, thereby lessening the risks of sepsis during chemotherapy-induced marrow failure. Such an approach may limit the need for granulocyte transfusions.
Although these agents will decrease the periods of neutropenia, they will not totally eliminate them. Furthermore, their efficacy in qualitative granulocyte defects has not been evaluated. Therefore, clinical situations will arise when granulocyte transfusions will be considered as part of the therapeutic armamentarium.
While the prophylactic administration of granulocyte transfusions to all neutropenic patients is unwarranted, it appears that granulocyte transfusions may be beneficial in patients with documented gram-negative infections that have failed to respond to appropriate antibiotic therapy for 48 to 72 hours. However, no conclusive data exists supporting their efficacy in other clinical situations including prophylaxis therapy, fever without bacteraemia, and infections of other aetiologies (fungal and gram-positive).
When the decision is made to administer granulocyte transfusions, an appropriate goal is the daily administration of granulocytes (ABO compatible) in a dose of 1 X 101O/M2/day (15 ml/kg/day of concentrate containing at least 1 X 10 9 WBC/15 ml). The granulocytes should be irradiated prior to administration and administered through standard blood product tubing over three to four hours. As with the administration of any blood products, careful observation of the recipient for possible side-effects is necessary.
